Why Case-Based Evidence Matters
Beyond device specs, real-world experience demonstrates the TM-Flow System’s value in improving care. The following scenarios illustrate how objective data shapes decisions.
Case 1: Early Diabetic Neuropathy
A 55-year-old with type 2 diabetes had mild foot tingling. TM-Flow revealed reduced sudomotor conductance and low HRV, confirming early autonomic neuropathy.
Lifestyle and medication adjustments improved his symptoms within 6 months.
Case 2: Peripheral Arterial Disease
A 67-year-old smoker presented with calf cramps. ABI = 0.74 bilaterally. Referral for Doppler confirmed PAD. And antiplatelet therapy began early, preventing ulceration.
Case 3: Autonomic Dysfunction in Hypertension
A hypertensive patient had unexplained fatigue. HRV testing showed sympathetic over-activation. Adjusting medications and stress management normalized readings over 3 months.
Common Trends
- Earlier recognition of subclinical disease
- Better referral accuracy
- Enhanced patient engagement through visual data
FAQs
- Is TM-Flow validated clinically? Yes—used widely in primary and specialty care.
- How reliable are case findings? Consistent across thousands of in-office uses.
- Can data be trended over time? Yes, through serial testing.
- Is it safe for elderly patients? Yes, fully non-invasive.
- Can results guide medication? They guide further diagnostic or therapeutic action.
- Are results immediate? Yes—report generated in minutes.
Conclusion
Case experience underscores the TM-Flow System’s role in preventive and diagnostic care, helping clinicians identify disease earlier and manage it proactively.
The Value of Clinical Evidence in Diagnostic Device Adoption
For independent physicians adding autonomic and vascular screening, clinical case studies offer the most compelling proof of real-world impact.
Device specs and clinical theory carry weight. But actual patient stories show the value best. The TM-Flow System, offered through HealthWright Technologies’ CMAT Advantage program, has changed how practices detect and treat disease. These cases show what the data alone cannot.
Cases from CMAT Advantage practices share a common theme: early detection of conditions that standard care would have missed.
Abnormal Ankle-Brachial Index (ABI) readings help identify peripheral arterial disease in at-risk patients. Heart rate variability (HRV) and Ewing battery tests spot cardiac autonomic neuropathy early. Sudomotor testing reveals small-fiber damage in patients with borderline glucose levels.
Translating Screening Findings Into Improved Patient Outcomes
Early detection lets physicians act before problems become irreversible. When CMAT Advantage screening finds reduced blood flow in a patient with no symptoms, the care team can step in early. Options include medication changes, lifestyle coaching, and specialist referral. All of this happens before the patient develops pain, chronic wounds, or the need for surgery.
Early detection of cardiac autonomic neuropathy enables proactive cardiovascular risk management. This can reduce sudden cardiac events in high-risk patients.
HealthWright Technologies encourages partner practices to track their clinical outcomes. This supports internal quality improvement. It also adds to the growing evidence for routine autonomic and vascular screening in independent practices.
The CMAT Cloud platform makes this easy with centralized data storage and reporting tools. Practices can review trends and share results in a structured way.
Ready to get started? Learn how HealthWright Advantage bundles the device, training, and ongoing support your practice needs — backed by a 90-day buyback guarantee.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis, treatment, and clinical decision-making.
Frequently Asked Questions
What do the TM-Flow System case studies demonstrate?
They illustrate how objective measurements from the TM-Flow System can support earlier clinical decisions. The scenarios show typical workflows and do not guarantee any specific patient outcome.
Are these case studies based on individual patients?
The scenarios are illustrative and used for education. Individual results vary, and the measurements support — rather than replace — a physician’s clinical judgment.
Which measurements are captured during an assessment?
A single non-invasive session can capture ankle-brachial index (CPT 93923), sudomotor function (CPT 95923), and heart-rate variability (CPT 95921). Code selection and coverage are the billing provider’s responsibility.
How can a practice apply these findings?
Objective findings can help prioritize follow-up, document medical necessity, and monitor change over time as part of a diagnostic program built around the CMAT Advantage System.
CPT codes are provided for informational purposes only and do not guarantee reimbursement. Verify code applicability and coverage with the relevant payer and your billing department before submitting claims. CPT® is a registered trademark of the American Medical Association.
Ready to see the CMAT Advantage in your practice?
Book a free 15-minute demo — see the full PAD + autonomic workup and triple-CPT billing potential, with no obligation. Backed by our 90-day buyback guarantee.
Book a Free Demo →
